Zimmer Biomet Holdings (Zimmer Biomet Holdings) Risk Assessment

View and export this data going back to 2001. Start your Free Trial

What is Zimmer Biomet Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Zimmer Biomet Holdings is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Zimmer Biomet Holdings's Risk Assessment

For the Medical Devices subindustry, Zimmer Biomet Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zimmer Biomet Holdings's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Risk Assessment falls into.

Zimmer Biomet Holdings (NYSE:ZBH) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Zimmer Biomet Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Zimmer Biomet Holdings (Zimmer Biomet Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (NYSE:ZBH) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

ZIM:Germany ZBH:Austria

Address

345 East Main Street, Warsaw, IN, USA, 46580

Website

https://www.zimmerbiomet.com

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Executives

Syed A. Jafry	director	345 E. MAIN STREET, WARSAW IN 46580
Sreelakshmi Kolli	director	C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Christopher B Begley	director
Robert Hagemann	director	3 GIRALDA FARMS, MADISON NJ 07940
Michael W Michelson	director	2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Betsy J Bernard	director	711 HIGH STREET, DES MOINES IA 50392-0300
Arthur J Higgins	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Chad F Phipps	officer: Assoc. Gen. Counsel, Corp. Sec	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Zuilen Wilfred Van	officer: Pres, Europe, M. East & Africa	345 E. MAIN STREET, WARSAW IN 46580
Paul A Stellato	officer: VP, Controller & CAO	C/O XYLEM INC, 1 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Sang Yi	officer: President, Asia Pacific	345 E. MAIN STREET, WARSAW IN 46580
Lori Winkler	officer: SVP and CHRO	345 E. MAIN STREET, WARSAW IN 46580
Rachel Ellingson	officer: SVP & CSO	345 E MAIN STREET, WARSAW K7 46580
Bryan C Hanson	director, officer: President and CEO	ZIMMER BIOMET HOLDINGS, 345 E. MAIN STREET, WARSAW IN 46580
Aure Bruneau	officer: Group President	345 E. MAIN STREET, WARSAW IN 46580